Precipio (NASDAQ:PRPO – Get Free Report) and P3 Health Partners (NASDAQ:PIII – Get Free Report) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, analyst recommendations, institutional ownership, risk, valuation, profitability and dividends.
Risk & Volatility
Precipio has a beta of 1.19, suggesting that its stock price is 19% more volatile than the S&P 500. Comparatively, P3 Health Partners has a beta of 0.57, suggesting that its stock price is 43% less volatile than the S&P 500.
Insider and Institutional Ownership
10.5% of Precipio shares are held by institutional investors. Comparatively, 7.8% of P3 Health Partners shares are held by institutional investors. 16.9% of Precipio shares are held by company insiders. Comparatively, 17.8% of P3 Health Partners shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Profitability
| Net Margins | Return on Equity | Return on Assets | |
| Precipio | -1.51% | -2.78% | -1.84% |
| P3 Health Partners | -10.14% | -302.33% | -20.72% |
Valuation & Earnings
This table compares Precipio and P3 Health Partners”s gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Precipio | $24.05 million | 2.09 | -$360,000.00 | ($0.25) | -113.20 |
| P3 Health Partners | $1.46 billion | 0.01 | -$147.95 million | ($45.20) | -0.06 |
Precipio has higher earnings, but lower revenue than P3 Health Partners. Precipio is trading at a lower price-to-earnings ratio than P3 Health Partners, indicating that it is currently the more affordable of the two stocks.
Analyst Ratings
This is a summary of recent recommendations and price targets for Precipio and P3 Health Partners, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Precipio | 1 | 0 | 0 | 0 | 1.00 |
| P3 Health Partners | 1 | 2 | 1 | 0 | 2.00 |
P3 Health Partners has a consensus target price of $3.50, indicating a potential upside of 34.62%. Given P3 Health Partners’ stronger consensus rating and higher possible upside, analysts clearly believe P3 Health Partners is more favorable than Precipio.
Summary
Precipio beats P3 Health Partners on 8 of the 14 factors compared between the two stocks.
About Precipio
Precipio, Inc., a healthcare solutions company, provides diagnostic products, reagents, and services in the United States. It provides diagnostic blood cancer testing services. The company offers IV-Cell, a proprietary cell culture media that enables simultaneous culturing of four hematopoietic cell lineages; and HemeScreen, a suite of robust genetic diagnostic panels. It offers biomarker testing and clinical project services to bio-pharma customers. The company is based in New Haven, Connecticut.
About P3 Health Partners
P3 Health Partners Inc., a patient-centered and physician-led population health management company, provides superior care services in the United States. It operates clinics and wellness centers. P3 Health Partners Inc. was founded in 2020 and is based in Henderson, Nevada.
Receive News & Ratings for Precipio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Precipio and related companies with MarketBeat.com's FREE daily email newsletter.
